Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML [Phase 3]
Phase 3 trial investigating azacitidine combined with venetoclax and ATRA for newly diagnosed acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation [Phase 3]
A Phase 3 randomized trial comparing Fludarabine and Busulfan versus Fludarabine, Busulfan plus Total Body Irradiation in patients with myel…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML [Phase 3]
Phase 3 trial evaluating CPI-613 with HD cytarabine and mitoxantrone versus HD cytarabine and mitoxantrone in older patients with relapsed/r…
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 clinical trial update for pyronaridine in acute myeloid leukemia and acute lymphoblastic leukemia is in progress with unknown status…
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy [Phase 1, Phase 2]
Phase 1/2 study evaluating two combinations of IDH-mutant targeted therapies plus azacitidine in newly diagnosed AML patients who are not ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]
Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission [Phase 2]
Phase 2 clinical trial evaluating lenalidomide for high-risk acute myeloid leukemia in remission has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of GTB-3550 Tri-Specific Killer Engager (TriKE) for high-risk hematologic malignancies has been terminated; results posted i…
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML [Phase 2]
Phase 2 clinical trial evaluating relatlimab with nivolumab and 5-azacytidine for acute myeloid leukemia (AML).
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm [Phase 1, Phase 2]
Clinical trial update on combining gemtuzumab ozogamicin with G-CSF, cladribine, cytarabine, and mitoxantrone in untreated AML and high-grad…
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML [Phase 2]
Phase 2 trial evaluating HVA regimens as salvage therapy for refractory/relapsed acute myeloid leukemia and related erythroid leukemias; stu…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS [Phase 3]
Phase 3 trial comparing NiCord (omidubicel) stem cell transplantation to standard umbilical cord blood in patients with hematologic malignan…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating mitoxantrone with clofarabine for recurrent non-Hodgkin lymphoma or acute leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the safety and efficacy of Esperanza Extract (PA001) for various neoplastic conditions; current status i…
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy [Phase 2]
Phase 2 clinical trial evaluating alvocidib in patients with relapsed/refractory acute myeloid leukemia after venetoclax-containing therapy;…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML [Phase 1, Phase 2]
Clinical trial evaluating nivolumab in combination with 5-azacytidine for childhood relapsed/refractory acute myeloid leukemia (Phase 1/Phas…
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating leukemic dendritic cell vaccination in patients with acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia [Phase 2]
Phase 2 trial update on efficacy and safety of allogeneic dendritic cell therapy DCP-001 in Acute Myeloid Leukemia in remission.
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow [Phase 2]
Phase 2 trial update on specialized blood cell transplants for cancers of the blood and bone marrow; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML [Phase 2]
Phase 2 clinical trial update for Clofarabine, Cytarabine and Mitoxantrone (CLAM) in relapsed or refractory acute myeloid leukemia is comple…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) [Phase 3]
Phase 3 clinical trial update on quizartinib in combination with standard chemotherapy and as continuation therapy for newly diagnosed FLT3-…
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Oral Arsenic Trioxide for NPM1-mutated AML [Phase 2]
Phase 2 clinical trial update evaluating oral arsenic trioxide for NPM1-mutated AML (NPMc+ AML).
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) [Phase 3]
This Phase 3 trial compares pevonedistat plus azacitidine versus azacitidine alone as first-line therapy for higher-risk myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation [Phase 3]
Phase 3 trial evaluating enasidenib (AG-221) versus conventional care in older adults with late-stage IDH2-mutant acute myeloid leukemia has…
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia [Phase 2]
Phase 2 trial assessing CPX-351 for induction/consolidation in older adults with secondary or high-risk acute myeloid leukemia has completed…